AOD-9604: The Growth Hormone Fragment That Did Not Meet Its Endpoint

AOD-9604 is a fragment of human growth hormone — amino acids 176 to 191, the tail end of the molecule. The premise was elegant: isolate the region associated with fat metabolism and leave behind the parts responsible for growth-promoting effects.

It went through a genuine clinical development programme for obesity. Knowing how that programme ended is more informative than any dosing chart.

The premise

Growth hormone affects both fat metabolism and tissue growth, and the growth effects limit how far it can be pushed for metabolic purposes. Animal work indicated the C-terminal fragment retained lipolytic activity without stimulating the IGF-1 axis in the same way.

If that separation held in humans, the result would be fat-loss activity without the drawbacks of growth hormone itself. That was the hypothesis a company took into trials.

What happened in development

AOD-9604 progressed into human trials for obesity. The programme did not produce a result sufficient to carry it forward to approval, and development for that indication did not continue to a marketed product.

It is still described in marketing as a "fat-loss peptide", generally citing the preclinical rationale rather than the trial outcome. Both are part of the record; only one of them tested the hypothesis in people.

The vial math

AOD-9604 is supplied lyophilised, commonly in 2 mg or 5 mg vials, with figures discussed in micrograms.

The peptide calculator converts any vial size and target into units.

Storage

Storage is the same as any reconstituted vial: 2–8 °C, protected from light, never frozen, and bounded by the shorter of peptide stability and the 28-day limit on bacteriostatic water. The bacteriostatic water guide covers the detail.

What the fragment hypothesis assumed

The reasoning behind AOD-9604 is worth understanding because the same reasoning appears throughout peptide marketing: take a large molecule with mixed effects, isolate the region responsible for the effect you want, and discard the rest.

That approach assumes three things, and each is a real assumption rather than a given:

1. That the activity is localised. Some functions depend on the whole folded protein rather than a linear stretch of it, in which case a fragment carries the sequence but not the function.

2. That the fragment is stable. A short peptide cut from a protected interior may be degraded far faster once exposed.

3. That the animal result transfers. Rodent lipid metabolism is not human lipid metabolism, and the trial stage is precisely where that gets tested.

AOD-9604 is a case where the hypothesis was coherent, was funded, reached human trials, and did not produce a result that carried it forward. That is a more complete story than most peptides in this category can offer.

Reading the marketing

Listings for AOD-9604 typically describe it as a "fat-loss peptide" or "lipolytic fragment", language taken from the preclinical rationale. Both descriptions are accurate about what it was designed to be, and neither describes what the human trials found.

The distinction to hold onto: designed for and demonstrated to are different claims. The guide to reading a certificate of analysis covers the separate question of whether a given vial contains what the label says at all.

Frequently asked questions

Is AOD-9604 the same as HGH?

No. It is a 16-amino-acid fragment of the 191-amino-acid hormone, selected specifically to exclude the growth-promoting regions.

Does it raise IGF-1?

The premise of the fragment was that it would not, and that separation is the reason it was pursued. Whether it delivers a meaningful metabolic effect in humans is the question the trial programme did not resolve favourably.

Why is it still sold if trials did not succeed?

Research-chemical supply is not gated on clinical outcomes. A compound that failed an endpoint remains just as synthesisable as one that never entered trials, and marketing tends to cite the preclinical rationale.